Genmab

	13/11 18:51 af Solsen	Epco will be a huge asset.
	13/11 18:50 af Solsen	I think they said more data on GEN1046 in 2021.
	13/11 18:26 af DevOp	Aggressively recruiting i gen1046 expansion cohorts, results soon - det kunne godt lyde som før Asco...
	13/11 18:25 af GeorgeBest	Mere end nogensinde, jeg tror der startes 7-8 epco trials i løbet af kort tid, Tahi mener de hastigt haler ind på Roche
	13/11 18:25 af E L	New Data Build on Growing Evidence Supporting TEPEZZA® Efficacy in Thyroid Eye Disease (TED), Including in Patients With Less Severe Disease and Longer Disease Duration (link)
	13/11 18:21 af GeorgeBest	Tahi seems to be the new star in the bar ;-)
	13/11 18:20 af GeorgeBest	:-D
	13/11 18:20 af GeorgeBest	Grrrr only up 53% this year D-)
	13/11 18:18 af E L	i thought it was quite funny how Tahi Ahmadi could barely stop smiling when talking about Epco and 1046 lol, we was clearly very excited
	13/11 18:17 af E L	great presentation.
	13/11 18:16 af E L	yes it is just horrible , when are we ever going to make any money on this stock ??? :-D
	13/11 18:14 af AaBforever	Genmab i en nøddeskal...det skal vi lære at leve med...:-)
	13/11 18:10 af svak	En spændende dag med mange gode "ting" - men som desværre igen, igen giver en negativ kursudvikling. Det er ligesom det hænger ved en lovende pipelineudvikling sker der en negativ kursudvikling :)
	13/11 18:04 af E L	and where i earlier suggested that Colorectal cancer and Ovarian cancer will not continue to the expansion phase, they are probably the 2 'secret' ones?
	13/11 17:58 af Solsen	Pts i expansion cohorts med SD og PR er still ongoing i GEN1046.
	13/11 17:53 af DevOp	Og Gen1046 viser også effekt i pts med lave PD-L1 niveauer. Sammen med virkning i ICI-refraktære pts virker det da som ret gode muligheder
	13/11 17:49 af Solsen	Hexa38 data i 2021. Potentiale ikke blot i MM, men også i MCL, DLBCL og solide ;-)
	13/11 17:38 af Solsen	Han synes ikke figuren var høj nok - han gættede på $3bn i revenue. Mon ikke han overfortolker :-)
	13/11 17:35 af w	Novod virkede noget skeptisk over 2025e
	13/11 17:32 af Solsen	Som med epco kan studierne gå meget hurtigt. De tager dog forbehold for SAE ;-)
	13/11 17:31 af Solsen	ASH har preclinical data der er meget imponerende. Påbegynder vel studier i mennesker meget snart.
	13/11 17:23 af Bulder	noget om hexa cd38?
	13/11 17:17 af Solsen	Epco tror de meget på er best in class. Sc version er tillige vigtigt kommercielt. ASH bliver interessant igen i år.
	13/11 17:09 af Solsen	DR5xDR5 næste år.

	13/11 17:04 af Solsen	GEN1046 er åbentlyst til mere end NSCLC. Flere data very soon.
	13/11 16:54 af AaBforever	JvdW må op i tempo;-)
	13/11 16:53 af AaBforever	Kursen reagerer let negativ.
	13/11 16:36 af Solsen	Epco er voldsomt imponerende :-)
	13/11 15:37 af Solsen	Dejligt med live billeder :-)
	13/11 14:30 af E L	another Dara label extension to follow shortly - Positive recommendations on extensions of indications Name of medicine Kyprolis INN carfilzomib Marketing-authorisation holder Amgen Europe B.V. More information Kyprolis: Pending EC decision (Extension of existing indication to include combination of Kyprolis with daratumumab and dexamethasone)
	13/11 14:00 af E L	LYRA / Dara-CyBorD completed (link)
	13/11 13:54 af E L	A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in R/R DLBCL (link)
	13/11 13:54 af E L	nice timing:
	13/11 13:42 af Solsen	Siden er nede. Help ....
	13/11 13:06 af Helge Larsen/PI-redaktør	Reminder: (link)
	13/11 11:48 af DevOp	thx, Bulder - that's a pretty comprehensive list :- )
	13/11 11:30 af Bulder	Asco would be a good guess
	13/11 11:30 af Bulder	One of these ;-) (link)
	13/11 11:22 af DevOp	Seems data from the NSCLC expansion is unlikely to be presented already, but aren't they compelled to present the data either at a conference or at least one of the medical journals? And if that's the case, I guess ASH would be no good as it's only hematology - but which conference would be a good guess for results then - something in May/June?
	13/11 11:16 af E L	lol, how to make a headline that will get people to click on your article, "Janssen combines Darzalex with COVID drug in new multiple myeloma submission" (link)
	13/11 10:54 af E L	Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (link)
	13/11 10:46 af E L	The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications (link)
	13/11 10:45 af E L	i would not expect too much extra data, efficacy data was Sep 29, NSCLC expansian was Oct 12?
	13/11 10:41 af Sukkeralf	Tror jeg ikke vi får - måske lidt løst mellem linierne fra Jan
	13/11 10:20 af Solsen	Håber på nye opdaterede data i dag. De må kende resultaterne på yderligere et par måneder af forsøget.
	13/11 09:54 af bibob	And the MTD was not yet reached.
	13/11 09:41 af bibob	Jeg hæftede mig også ved de forskellige doser.
	13/11 09:39 af Bulder	Tak bibob. “From the point of view of safety, the [toxicity] profile [of GEN1046] is durable, and it was very much focused on liver safety since previous agonists directed to 4-1BB had problems with this,” noted Melero.
	13/11 08:34 af bibob	OncLive. DuoBody PD-L1 x4 -1BB (link)
	13/11 08:33 af bibob	God morgen. :-)